🇺🇸 FDA
Patent

US 12427173

Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

granted A61KA61K2035/115A61K2039/505

Quick answer

US patent 12427173 (Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies) held by Biomed Valley Discoveries, Inc. expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2035/115, A61K2039/505, A61K2039/54, A61K2039/545